{
    "abstract": "Background: Hepatitis B virus (HBV) remains a major public health issue, although it is a vaccine-preventable disease. Adults with diabetes are at greater risk of contracting HBV than the general population. Commonly used 3-dose HBV vaccines have reduced immunogenicity in older individuals and in those with diabetes mellitus. Methods: In this post hoc analysis of a phase 3 clinical trial, participants with type 2 diabetes mellitus aged 60\u201370 years received either 2-dose HBsAg/CpG 1018 (HEPLISAV-B\u00ae, n = 327) at 0 and 4 weeks and placebo at 24 weeks or 3-dose HBsAg/alum (Engerix-B\u00ae, n = 153) at 0, 4, and 24 weeks. Immunogenicity, including seroprotection rate (SPR) at week 28, and safety were assessed by subgroup (sex, body mass index, and smoking status). SPR was defined as antibody against hepatitis B surface antigen serum concentration \u226510 mIU/mL. Results: The SPR at week 28 was significantly higher with HBsAg/CpG 1018 (85.8% [235/274]) than with HBsAg/alum (58.5% [76/130]) in the per-protocol analysis, for an overall difference of 27.3% (95% CI, 18.0\u201336.8). SPRs with HBsAg/CpG 1018 were consistently markedly higher compared with HBsAg/alum, regardless of sex, body mass index, or smoking status. Adverse events and deaths were comparable between groups. Conclusions: Two-dose HBsAg/CpG 1018 provides a higher level of seroprotection against HBV than does a 3-dose vaccine (HBsAg/alum) with a similar safety profile in patients aged 60\u201370 years with type 2 diabetes mellitus. Study identifier: NCT02117934.",
    "author_highlights": [
        {
            "endOffset": 12032,
            "sentence": "HBsAg/CpG 1018 is a 2-dose hepatitis B vaccine.",
            "startOffset": 11985
        },
        {
            "endOffset": 12117,
            "sentence": "Adults with T2DM are at greater risk of contracting HBV than the general population.",
            "startOffset": 12033
        },
        {
            "endOffset": 12190,
            "sentence": "HBV vaccination is important in individuals with T2DM 60 years or older.",
            "startOffset": 12118
        },
        {
            "endOffset": 12262,
            "sentence": "HBsAg/CpG 1018 provides higher SPRs against HBV than 3-dose HBsAg/alum.",
            "startOffset": 12191
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Aaron M.",
                    "initial": "A.M.",
                    "last": "Harris"
                },
                {
                    "first": "Kashif",
                    "initial": "K.",
                    "last": "Iqbal"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Schillie"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Britton"
                },
                {
                    "first": "Marion A.",
                    "initial": "M.A.",
                    "last": "Kainer"
                },
                {
                    "first": "Stacy",
                    "initial": "S.",
                    "last": "Tressler"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Vellozzi"
                }
            ],
            "doi": "10.15585/mmwr.mm6503a2",
            "firstpage": "47",
            "issn": "01492195",
            "lastpage": "50",
            "pmid": "26821369",
            "pub_year": 2016,
            "title": "Increases in acute hepatitis B virus infections \u2014 Kentucky, Tennessee, and West Virginia, 2006\u20132013",
            "volume": "65"
        },
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "Meredith L.",
                    "initial": "M.L.",
                    "last": "Reilly"
                },
                {
                    "first": "Sarah F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Smith"
                },
                {
                    "first": "Tasha",
                    "initial": "T.",
                    "last": "Poissant"
                },
                {
                    "first": "Candace W.",
                    "initial": "C.W.",
                    "last": "Vonderwahl"
                },
                {
                    "first": "Kristin",
                    "initial": "K.",
                    "last": "Gerard"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Baumgartner"
                },
                {
                    "first": "Lynne",
                    "initial": "L.",
                    "last": "Mercedes"
                },
                {
                    "first": "Kristin",
                    "initial": "K.",
                    "last": "Sweet"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Muleta"
                },
                {
                    "first": "Daniel J.",
                    "initial": "D.J.",
                    "last": "Zaccaro"
                },
                {
                    "first": "Monina",
                    "initial": "M.",
                    "last": "Klevens"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.1177/193229681200600417",
            "firstpage": "858",
            "issn": "19322968",
            "lastpage": "866",
            "pmid": "22920812",
            "pub_year": 2012,
            "title": "Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus",
            "volume": "6"
        },
        "b0030": {
            "authors": [
                {
                    "first": "S. F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Xing"
                },
                {
                    "first": "T. V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Hu"
                }
            ],
            "doi": "10.1111/j.1365-2893.2012.01616.x",
            "firstpage": "674",
            "issn": "13520504",
            "lastpage": "676",
            "pmid": "22863272",
            "pub_year": 2012,
            "title": "Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999-2010",
            "volume": "19"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Sawyer"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Hoerger"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                },
                {
                    "first": "Sarah F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "Dale",
                    "initial": "D.",
                    "last": "Hu"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Spradling"
                },
                {
                    "first": "Kathy K.",
                    "initial": "K.K.",
                    "last": "Byrd"
                },
                {
                    "first": "Jian",
                    "initial": "J.",
                    "last": "Xing"
                },
                {
                    "first": "Meredith L.",
                    "initial": "M.L.",
                    "last": "Reilly"
                },
                {
                    "first": "Rania A.",
                    "initial": "R.A.",
                    "last": "Tohme"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Moorman"
                },
                {
                    "first": "Emily A.",
                    "initial": "E.A.",
                    "last": "Smith"
                },
                {
                    "first": "Brittney N.",
                    "initial": "B.N.",
                    "last": "Baack"
                },
                {
                    "first": "Ruth B.",
                    "initial": "R.B.",
                    "last": "Jiles"
                },
                {
                    "first": "Monina",
                    "initial": "M.",
                    "last": "Klevens"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Ward"
                },
                {
                    "first": "Henry S.",
                    "initial": "H.S.",
                    "last": "Kahn"
                },
                {
                    "first": "Fangjun",
                    "initial": "F.",
                    "last": "Zhou"
                }
            ],
            "firstpage": "1709",
            "issn": "01492195",
            "lastpage": "1711",
            "pmid": "22189894",
            "pub_year": 2011,
            "title": "Use of hepatitis B vaccination for adults with diabetes mellitus: Recommendations of the advisory committee on immunization practices (ACIP)",
            "volume": "60"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Zobair",
                    "initial": "Z.",
                    "last": "Younossi"
                },
                {
                    "first": "Katrin",
                    "initial": "K.",
                    "last": "Kochems"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "de Ridder"
                },
                {
                    "first": "Desmond",
                    "initial": "D.",
                    "last": "Curran"
                },
                {
                    "first": "Eveline M.",
                    "initial": "E.M.",
                    "last": "Bunge"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "de Moerlooze"
                }
            ],
            "doi": "10.1080/21645515.2017.1353850",
            "firstpage": "2695",
            "issn": "21645515",
            "lastpage": "2706",
            "pmid": "28742983",
            "pub_year": 2017,
            "title": "Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease",
            "volume": "13"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Huijuan",
                    "initial": "H.",
                    "last": "Zhu"
                },
                {
                    "first": "Yiying",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Lugang",
                    "initial": "L.",
                    "last": "Yu"
                },
                {
                    "first": "Yunfang",
                    "initial": "Y.",
                    "last": "Xu"
                },
                {
                    "first": "Hui",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Yi",
                    "initial": "Y.",
                    "last": "Ding"
                },
                {
                    "first": "Aili",
                    "initial": "A.",
                    "last": "Wang"
                },
                {
                    "first": "Xingxiang",
                    "initial": "X.",
                    "last": "Liu"
                },
                {
                    "first": "Chen",
                    "initial": "C.",
                    "last": "Dong"
                }
            ],
            "doi": "10.3855/jidc.7656",
            "firstpage": "837",
            "issn": "20366590",
            "lastpage": "844",
            "pmid": "27580329",
            "pub_year": 2016,
            "title": "Serological and molecular analysis on the relationships between type 2 diabetes mellitus and hepatitis B virus infection",
            "volume": "10"
        },
        "b0050": {
            "authors": [
                {
                    "first": "David N.",
                    "initial": "D.N.",
                    "last": "Fisman"
                },
                {
                    "first": "Deepak",
                    "initial": "D.",
                    "last": "Agrawal"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Leder"
                }
            ],
            "doi": "10.1086/344271",
            "firstpage": "1368",
            "issn": "10584838",
            "lastpage": "1375",
            "pmid": "12439800",
            "pub_year": 2002,
            "title": "The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis",
            "volume": "35"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Bernd",
                    "initial": "B.",
                    "last": "Wolters"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Junge"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Dziuba"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Roggendorf"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00399-2",
            "firstpage": "3623",
            "issn": "0264410X",
            "lastpage": "3628",
            "pmid": "12922091",
            "pub_year": 2003,
            "title": "Immunogenicity of combined hepatitis A and B vaccine in elderly persons",
            "volume": "21"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Shigui",
                    "initial": "S.",
                    "last": "Yang"
                },
                {
                    "first": "Guo",
                    "initial": "G.",
                    "last": "Tian"
                },
                {
                    "first": "Yuanxia",
                    "initial": "Y.",
                    "last": "Cui"
                },
                {
                    "first": "Cheng",
                    "initial": "C.",
                    "last": "Ding"
                },
                {
                    "first": "Min",
                    "initial": "M.",
                    "last": "Deng"
                },
                {
                    "first": "Chengbo",
                    "initial": "C.",
                    "last": "Yu"
                },
                {
                    "first": "Kaijin",
                    "initial": "K.",
                    "last": "Xu"
                },
                {
                    "first": "Jingjing",
                    "initial": "J.",
                    "last": "Ren"
                },
                {
                    "first": "Jun",
                    "initial": "J.",
                    "last": "Yao"
                },
                {
                    "first": "Yiping",
                    "initial": "Y.",
                    "last": "Li"
                },
                {
                    "first": "Qing",
                    "initial": "Q.",
                    "last": "Cao"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Chen"
                },
                {
                    "first": "Tiansheng",
                    "initial": "T.",
                    "last": "Xie"
                },
                {
                    "first": "Chencheng",
                    "initial": "C.",
                    "last": "Wang"
                },
                {
                    "first": "Bing",
                    "initial": "B.",
                    "last": "Wang"
                },
                {
                    "first": "Chen",
                    "initial": "C.",
                    "last": "Mao"
                },
                {
                    "first": "Bing",
                    "initial": "B.",
                    "last": "Ruan"
                },
                {
                    "first": "Tian'An",
                    "initial": "T.",
                    "last": "Jiang"
                },
                {
                    "first": "Lanjuan",
                    "initial": "L.",
                    "last": "Li"
                }
            ],
            "doi": "10.1038/srep27251",
            "issn": "20452322",
            "pmid": "27324884",
            "pub_year": 2016,
            "title": "Factors influencing immunologic response to hepatitis B vaccine in adults",
            "volume": "6"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Matthew F.",
                    "initial": "M.F.",
                    "last": "Daley"
                },
                {
                    "first": "Karen A.",
                    "initial": "K.A.",
                    "last": "Hennessey"
                },
                {
                    "first": "Cindy M.",
                    "initial": "C.M.",
                    "last": "Weinbaum"
                },
                {
                    "first": "Shannon",
                    "initial": "S.",
                    "last": "Stokley"
                },
                {
                    "first": "Laura P.",
                    "initial": "L.P.",
                    "last": "Hurley"
                },
                {
                    "first": "Lori A.",
                    "initial": "L.A.",
                    "last": "Crane"
                },
                {
                    "first": "Brenda L.",
                    "initial": "B.L.",
                    "last": "Beaty"
                },
                {
                    "first": "Jennifer C.",
                    "initial": "J.C.",
                    "last": "Barrow"
                },
                {
                    "first": "Christine I.",
                    "initial": "C.I.",
                    "last": "Babbel"
                },
                {
                    "first": "L. Miriam",
                    "initial": "L.M.",
                    "last": "Dickinson"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "Kempe"
                }
            ],
            "doi": "10.1016/j.amepre.2009.01.037",
            "firstpage": "491",
            "issn": "07493797",
            "lastpage": "496",
            "pmid": "19362798",
            "pub_year": 2009,
            "title": "Physician Practices Regarding Adult Hepatitis B Vaccination. A National Survey",
            "volume": "36"
        },
        "b0070": {
            "authors": [
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Ladak"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Gjelsvik"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Feller"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Rosenthal"
                },
                {
                    "first": "B. T.",
                    "initial": "B.T.",
                    "last": "Montague"
                }
            ],
            "doi": "10.1007/s15010-011-0241-2",
            "firstpage": "405",
            "issn": "03008126",
            "lastpage": "413",
            "pmid": "22237474",
            "pub_year": 2012,
            "title": "Hepatitis B in the United States: Ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007",
            "volume": "40"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Matthew J.",
                    "initial": "M.J.",
                    "last": "Alcusky"
                },
                {
                    "first": "Jayne",
                    "initial": "J.",
                    "last": "Pawasauskas"
                }
            ],
            "doi": "10.2337/diaclin.33.3.116",
            "firstpage": "116",
            "issn": "08918929",
            "lastpage": "122",
            "pub_year": 2015,
            "title": "Adherence to guidelines for hepatitis B, pneumococcal, and influenza vaccination in patients with diabetes",
            "volume": "33"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Walter W.",
                    "initial": "W.W.",
                    "last": "Williams"
                },
                {
                    "first": "Peng Jun",
                    "initial": "P.J.",
                    "last": "Lu"
                },
                {
                    "first": "Alissa",
                    "initial": "A.",
                    "last": "O'Halloran"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Kim"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Grohskopf"
                },
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Tami H.",
                    "initial": "T.H.",
                    "last": "Skoff"
                },
                {
                    "first": "Noele P.",
                    "initial": "N.P.",
                    "last": "Nelson"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Lauri E.",
                    "initial": "L.E.",
                    "last": "Markowitz"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Rodriguez-Lainz"
                },
                {
                    "first": "Amy Parker",
                    "initial": "A.P.",
                    "last": "Fiebelkorn"
                }
            ],
            "doi": "10.15585/mmwr.ss6611a1",
            "firstpage": "1",
            "issn": "15460738",
            "lastpage": "28",
            "pmid": "28472027",
            "pub_year": 2017,
            "title": "Surveillance of vaccination coverage among adult populations-United States, 2015",
            "volume": "66"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Brian J.",
                    "initial": "B.J.",
                    "last": "Ward"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Smith"
                },
                {
                    "first": "Donna",
                    "initial": "D.",
                    "last": "MacKinnon-Cameron"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "J. Tyler",
                    "initial": "J.T.",
                    "last": "Martin"
                }
            ],
            "doi": "10.4161/hv.24256",
            "firstpage": "1438",
            "issn": "21645515",
            "lastpage": "1444",
            "pmid": "23571179",
            "pub_year": 2013,
            "title": "Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine",
            "volume": "9"
        },
        "b0090": {
            "authors": [
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Kyle"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Blumenau"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Davis"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Martin L.",
                    "initial": "M.L.",
                    "last": "Kabongo"
                },
                {
                    "first": "Sean",
                    "initial": "S.",
                    "last": "Bennett"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                },
                {
                    "first": "Hamid",
                    "initial": "H.",
                    "last": "Namini"
                },
                {
                    "first": "J. Tyler",
                    "initial": "J.T.",
                    "last": "Martin"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.05.068",
            "firstpage": "5300",
            "issn": "0264410X",
            "lastpage": "5305",
            "pmid": "23727002",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age",
            "volume": "31"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Julia M.",
                    "initial": "J.M.",
                    "last": "Janssen"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "J. Tyler",
                    "initial": "J.T.",
                    "last": "Martin"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.12.060",
            "firstpage": "833",
            "issn": "0264410X",
            "lastpage": "837",
            "pmid": "25576215",
            "pub_year": 2015,
            "title": "Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus",
            "volume": "33"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Julia M.",
                    "initial": "J.M.",
                    "last": "Janssen"
                },
                {
                    "first": "Sam",
                    "initial": "S.",
                    "last": "Jackson"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.05.070",
            "firstpage": "3614",
            "issn": "0264410X",
            "lastpage": "3618",
            "pmid": "26067185",
            "pub_year": 2015,
            "title": "Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age",
            "volume": "33"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Sam",
                    "initial": "S.",
                    "last": "Jackson"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Lentino"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Kopp"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Murray"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Ellison"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Rhee"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Shockey"
                },
                {
                    "first": "Lalith",
                    "initial": "L.",
                    "last": "Akella"
                },
                {
                    "first": "Kimberly",
                    "initial": "K.",
                    "last": "Erby"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Adams"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Bolshoun"
                },
                {
                    "first": "Tami",
                    "initial": "T.",
                    "last": "Bruce"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "Chuang"
                },
                {
                    "first": "Donna",
                    "initial": "D.",
                    "last": "DeSantis"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fiel"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Fitzgibbons"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Francyk"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Geisberg"
                },
                {
                    "first": "Son",
                    "initial": "S.",
                    "last": "Giep"
                },
                {
                    "first": "Narendra",
                    "initial": "N.",
                    "last": "Godbole"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Haas"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Halpern"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Inzerello"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Jennings"
                },
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Kaiser"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Kay"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Kirby"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Lending"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Levins"
                },
                {
                    "first": "Clifford",
                    "initial": "C.",
                    "last": "Molin"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Noss"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Kotek"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Reynolds"
                },
                {
                    "first": "Ernie",
                    "initial": "E.",
                    "last": "Riffer"
                },
                {
                    "first": "Douglas",
                    "initial": "D.",
                    "last": "Schumacher"
                },
                {
                    "first": "Randall",
                    "initial": "R.",
                    "last": "Severance"
                },
                {
                    "first": "Royce",
                    "initial": "R.",
                    "last": "Solano"
                },
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Tejada"
                },
                {
                    "first": "Leslie",
                    "initial": "L.",
                    "last": "Tharenos"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Throne"
                },
                {
                    "first": "Merle",
                    "initial": "M.",
                    "last": "Turner"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Wolf"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Woodruff"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2017.12.038",
            "firstpage": "668",
            "issn": "0264410X",
            "lastpage": "674",
            "pmid": "29289383",
            "pub_year": 2018,
            "title": "Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults",
            "volume": "36"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Van Der Meeren"
                },
                {
                    "first": "James T.",
                    "initial": "J.T.",
                    "last": "Peterson"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Beasley"
                },
                {
                    "first": "Peter R.",
                    "initial": "P.R.",
                    "last": "Ebeling"
                },
                {
                    "first": "Murdo",
                    "initial": "M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Nissen"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Rheault"
                },
                {
                    "first": "Richard W.",
                    "initial": "R.W.",
                    "last": "Simpson"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "De Ridder"
                },
                {
                    "first": "Priya D.",
                    "initial": "P.D.",
                    "last": "Crasta"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                },
                {
                    "first": "Andrew F.",
                    "initial": "A.F.",
                    "last": "Trofa"
                }
            ],
            "doi": "10.1080/21645515.2016.1164362",
            "firstpage": "2197",
            "issn": "21645515",
            "lastpage": "2203",
            "pmid": "27123743",
            "pub_year": 2016,
            "title": "Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus",
            "volume": "12"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Sarah F.",
                    "initial": "S.F.",
                    "last": "Schillie"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Spradling"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.2337/dc12-0312",
            "firstpage": "2690",
            "issn": "01495992",
            "lastpage": "2697",
            "pmid": "23173138",
            "pub_year": 2012,
            "title": "Immune response of hepatitis B vaccine among persons with diabetes: A systematic review of the literature",
            "volume": "35"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Randall",
                    "initial": "R.",
                    "last": "Hyer"
                },
                {
                    "first": "Darren K.",
                    "initial": "D.K.",
                    "last": "McGuire"
                },
                {
                    "first": "Biao",
                    "initial": "B.",
                    "last": "Xing"
                },
                {
                    "first": "Sam",
                    "initial": "S.",
                    "last": "Jackson"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Janssen"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.03.067",
            "firstpage": "2604",
            "issn": "0264410X",
            "lastpage": "2611",
            "pmid": "29628151",
            "pub_year": 2018,
            "title": "Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults",
            "volume": "36"
        },
        "b0125": {
            "authors": [
                {
                    "first": "G. F.",
                    "initial": "G.F.",
                    "last": "Reed"
                },
                {
                    "first": "B. D.",
                    "initial": "B.D.",
                    "last": "Meade"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Steinhoff"
                }
            ],
            "firstpage": "600",
            "issn": "00314005",
            "lastpage": "603",
            "pmid": "7659485",
            "pub_year": 1995,
            "title": "The reverse cumulative distribution plot: A graphic method for exploratory analysis of antibody data",
            "volume": "96"
        },
        "b0130": null,
        "b0135": null,
        "b0140": {
            "authors": [
                {
                    "first": "Francis E.",
                    "initial": "F.E.",
                    "last": "Andr\u00e9"
                }
            ],
            "doi": "10.1016/0002-9343(89)90525-1",
            "firstpage": "S14",
            "issn": "00029343",
            "lastpage": "S20",
            "pmid": "2528292",
            "pub_year": 1989,
            "title": "Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine",
            "volume": "87"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Mary Lou",
                    "initial": "M.L.",
                    "last": "Clements-Mann"
                },
                {
                    "first": "Gregory A.",
                    "initial": "G.A.",
                    "last": "Poland"
                },
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Jacobson"
                },
                {
                    "first": "Allen E.",
                    "initial": "A.E.",
                    "last": "Izu"
                },
                {
                    "first": "Doreen",
                    "initial": "D.",
                    "last": "Sakamoto"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Eiden"
                },
                {
                    "first": "Gary A.",
                    "initial": "G.A.",
                    "last": "Van Nest"
                },
                {
                    "first": "Henry H.",
                    "initial": "H.H.",
                    "last": "Hsu"
                }
            ],
            "doi": "10.1016/S0264-410X(99)00088-2",
            "firstpage": "2769",
            "issn": "0264410X",
            "lastpage": "2778",
            "pmid": "10438046",
            "pub_year": 1999,
            "title": "A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant",
            "volume": "17"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Ward"
                },
                {
                    "first": "Curtis",
                    "initial": "C.",
                    "last": "Cooper"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Predy"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Diaz-Mitoma"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Embree"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "McGeer"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Zickler"
                },
                {
                    "first": "Karl Heinz",
                    "initial": "K.H.",
                    "last": "Moltz"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Martz"
                },
                {
                    "first": "Ingo",
                    "initial": "I.",
                    "last": "Meyer"
                },
                {
                    "first": "Shelly",
                    "initial": "S.",
                    "last": "McNeil"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Martins"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "J. Tyler",
                    "initial": "J.T.",
                    "last": "Martin"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.01.087",
            "firstpage": "2556",
            "issn": "0264410X",
            "lastpage": "2563",
            "pmid": "22326642",
            "pub_year": 2012,
            "title": "Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age",
            "volume": "30"
        },
        "b0155": null,
        "b0160": null,
        "b0165": null,
        "b0170": null,
        "b0175": {
            "authors": [
                {
                    "first": "Parinaz K.",
                    "initial": "P.K.",
                    "last": "Ghaswalla"
                },
                {
                    "first": "Brandon J.",
                    "initial": "B.J.",
                    "last": "Patterson"
                },
                {
                    "first": "Wendy Y.",
                    "initial": "W.Y.",
                    "last": "Cheng"
                },
                {
                    "first": "Emilie",
                    "initial": "E.",
                    "last": "Duchesneau"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Macheca"
                },
                {
                    "first": "Mei Sheng",
                    "initial": "M.S.",
                    "last": "Duh"
                }
            ],
            "doi": "10.1080/21645515.2018.1489189",
            "firstpage": "2780",
            "issn": "21645515",
            "lastpage": "2785",
            "pmid": "29923789",
            "pub_year": 2018,
            "title": "Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis",
            "volume": "14"
        },
        "b0180": {
            "authors": [
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Oxman"
                },
                {
                    "first": "G. H.",
                    "initial": "G.H.",
                    "last": "Guyatt"
                }
            ],
            "doi": "10.7326/0003-4819-116-1-78",
            "firstpage": "78",
            "issn": "00034819",
            "lastpage": "84",
            "pmid": "1530753",
            "pub_year": 1992,
            "title": "A consumer's guide to subgroup analyses",
            "volume": "116"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Erika F.",
                    "initial": "E.F.",
                    "last": "Duffell"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Hedrich"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Mardh"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Mozalevskis"
                }
            ],
            "doi": "10.2807/1560-7917.ES.2017.22.9.30476",
            "issn": "1025496X",
            "pmid": "28277217",
            "pub_year": 2017,
            "title": "Towards elimination of hepatitis B and C in European union and European economic area countries: Monitoring the world health organization\u2019s global health sector strategy core indicators and scaling up key interventions",
            "volume": "22"
        },
        "b0190": {
            "authors": [
                {
                    "first": "E. F.",
                    "initial": "E.F.",
                    "last": "Duffell"
                },
                {
                    "first": "L. M.",
                    "initial": "L.M.",
                    "last": "Milne"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Seng"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Young"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Xavier"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "King"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Shukla"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ijaz"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1017/S0950268810001007",
            "firstpage": "327",
            "issn": "09502688",
            "lastpage": "335",
            "pmid": "20478083",
            "pub_year": 2011,
            "title": "Five hepatitis B outbreaks in care homes in the UK associated with deficiencies in infection control practice in blood glucose monitoring",
            "volume": "139"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Lale",
                    "initial": "L.",
                    "last": "Ozisik"
                },
                {
                    "first": "Mine Durusu",
                    "initial": "M.D.",
                    "last": "Tanriover"
                },
                {
                    "first": "Nursel Calik",
                    "initial": "N.C.",
                    "last": "Basaran"
                },
                {
                    "first": "S. Gul",
                    "initial": "S.G.",
                    "last": "Oz"
                },
                {
                    "first": "Serhat",
                    "initial": "S.",
                    "last": "Unal"
                }
            ],
            "doi": "10.1080/21645515.2015.1070999",
            "firstpage": "2806",
            "issn": "21645515",
            "lastpage": "2810",
            "pmid": "26366628",
            "pub_year": 2015,
            "title": "Missed opportunities for hepatitis B vaccination among diabetic patients",
            "volume": "11"
        },
        "b0200": null
    },
    "body_text": [
        {
            "endOffset": 25501,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In the HBsAg/CpG 1018 group, 1 (0.3%) participant experienced an immune-mediated AE of special interest related to the study treatment.",
            "startOffset": 25366,
            "title": "Safety"
        },
        {
            "endOffset": 20987,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0040",
            "sentence": "Adverse events (AEs) were assessed for all participants in the cohort aged 60 to 70 years with type 2 DM who received at least 1 injection of study vaccine.",
            "startOffset": 20831,
            "title": "Safety"
        },
        {
            "endOffset": 23227,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Similarly, in the mITT analysis, the SPR at week 28 was significantly higher for HBsAg/CpG 1018 than for HBsAg/alum, with a treatment effect difference of 27.6% (95% CI, 18.9\u201336.5%) (Fig. 2B).",
            "startOffset": 23035,
            "title": "Immunogenicity by seroprotection rates"
        },
        {
            "endOffset": 28943,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 28795,
                    "startOffset": 28792
                },
                "b0035": {
                    "endOffset": 28942,
                    "startOffset": 28939
                }
            },
            "secId": "s0075",
            "sentence": "In the United States, people with DM are at greater risk of contracting HBV [4], with the odds of a person with diabetes aged \u226560 years developing acute HBV being 1.5 times higher than age-matched controls without diabetes [7].",
            "startOffset": 28716,
            "title": "Discussion"
        },
        {
            "endOffset": 27710,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 27710,
                    "startOffset": 27706
                }
            },
            "secId": "s0075",
            "sentence": "A prospective, controlled study of 3-dose recombinant hepatitis B vaccine immunogenicity and safety found only 58.2% of participants with DM aged \u226560 years achieved seroprotection compared with 70.2% of age matched non-diabetic controls.[22]",
            "startOffset": 27469,
            "title": "Discussion"
        },
        {
            "endOffset": 30310,
            "parents": [],
            "secId": "s0075",
            "sentence": "Another limitation is the relatively homogeneous population with respect to race and ethnicity.",
            "startOffset": 30215,
            "title": "Discussion"
        },
        {
            "endOffset": 26533,
            "parents": [],
            "secId": "s0075",
            "sentence": "The safety profile of the 2-dose HBsAg/CpG 1018 vaccine is similar to that of a commonly used 3-dose vaccine.",
            "startOffset": 26424,
            "title": "Discussion"
        },
        {
            "endOffset": 21472,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The modified intent-to-treat (mITT) analysis was comprised of enrolled participants with type 2 DM aged 60\u201370 years who received at least 1 injection and underwent at least 1 immunogenicity evaluation.",
            "startOffset": 21271,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 18237,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accord with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation guidelines and with applicable local, legal, and regulatory requirements.",
            "startOffset": 18028,
            "title": "Study design"
        },
        {
            "endOffset": 20051,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0035",
            "sentence": "The primary immunogenicity end point for the phase 3 study was at week 28 in participants with DM.",
            "startOffset": 19953,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24646,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "A total of 210 (64.2%) participants in the HBsAg/CpG 1018 group reported an MAE with 77 (23.5%) participants who experienced a grade 3 or 4 MAE.",
            "startOffset": 24502,
            "title": "Safety"
        },
        {
            "endOffset": 25703,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No immune-mediated AEs of special interest were reported in the HBsAg/alum group.",
            "startOffset": 25622,
            "title": "Safety"
        },
        {
            "endOffset": 15179,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 15178,
                    "startOffset": 15175
                }
            },
            "secId": "s0005",
            "sentence": "Non-institutionalized persons with diagnosed DM have a 60% higher prevalence rate of HBV infection than those without DM (National Health and Nutrition Examination Survey) [6].",
            "startOffset": 15003,
            "title": "Introduction"
        },
        {
            "endOffset": 31513,
            "parents": [],
            "secId": "s0075",
            "sentence": "Unlike the Centers for Disease Control and Prevention and American Diabetes Association, the World Health Organization Regional Office for Europe, European Association for the Study of Diabetes, and the European Center for Disease Control do not provide guidance on vaccination of patients with DM.",
            "startOffset": 31215,
            "title": "Discussion"
        },
        {
            "endOffset": 18393,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol (DV2-HBV-23) and informed consent documents were approved by a central institutional review board (Sterling IRB, Atlanta, Georgia, USA).",
            "startOffset": 18238,
            "title": "Study design"
        },
        {
            "endOffset": 26423,
            "parents": [],
            "secId": "s0075",
            "sentence": "Invariably, SPRs achieved in participants with type 2 DM who were aged 60\u201370 years and older were significantly higher in the HBsAg/CpG 1018 group compared with the HBsAg/alum group, regardless of sex, BMI, or smoking status subgroup.",
            "startOffset": 26189,
            "title": "Discussion"
        },
        {
            "endOffset": 14331,
            "parents": [],
            "secId": "s0005",
            "sentence": "Hepatitis B virus (HBV) is highly transmissible and causes a serious and potentially life-threatening liver infection.",
            "startOffset": 14213,
            "title": "Introduction"
        },
        {
            "endOffset": 20462,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0035",
            "sentence": "In previous phase 3 trials, the SPR for HBsAg/CpG 1018 peaked at week 24 and SPR for HBsAg/alum peaked at week 28.",
            "startOffset": 20348,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21984,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "For GMCs, the 95% CI for HBsAg/CpG 1018 and HBsAg/alum were calculated using the 2-sided Clopper-Pearson method.",
            "startOffset": 21872,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28565,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 28386,
                    "startOffset": 28382
                }
            },
            "secId": "s0075",
            "sentence": "Given that DM is most prevalent in adults aged 65 years and older [34], we have a dual challenge for this population who is at increasing risk for HBV infection and disease and who do not respond well to traditional 3-dose, alum-adjuvanted vaccines.",
            "startOffset": 28316,
            "title": "Discussion"
        },
        {
            "endOffset": 24501,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The overall safety of HBsAg/CpG 1018 was comparable to that of HBsAg/alum.",
            "startOffset": 24427,
            "title": "Safety"
        },
        {
            "endOffset": 14844,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14843,
                    "startOffset": 14838
                },
                "b0015": {
                    "endOffset": 14843,
                    "startOffset": 14838
                }
            },
            "secId": "s0005",
            "sentence": "In the United States, it is estimated that 850,000 to 2.2 million people are living with chronic HBV infection, and despite the availability of prophylactic HBV vaccines, the rate of HBV infection is increasing, with the majority of new infections occurring in adults [2,3].",
            "startOffset": 14570,
            "title": "Introduction"
        },
        {
            "endOffset": 24095,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The reverse cumulative frequency curves for HBsAg/CpG 1018 and HBsAg/alum had distinctly different shapes (Fig. 5).",
            "startOffset": 23980,
            "title": "Immunogenicity by geometric mean concentration"
        },
        {
            "endOffset": 27922,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 27921,
                    "startOffset": 27908
                },
                "b0090": {
                    "endOffset": 27921,
                    "startOffset": 27908
                },
                "b0140": {
                    "endOffset": 27921,
                    "startOffset": 27908
                },
                "b0145": {
                    "endOffset": 27921,
                    "startOffset": 27908
                }
            },
            "secId": "s0075",
            "sentence": "Notably, results from a Vaccine Safety Datalink study showed that only half of adults receive all 3 doses, and it has been demonstrated that the third dose is essential for reliable seroprotection [17,18,28,29].",
            "startOffset": 27711,
            "title": "Discussion"
        },
        {
            "endOffset": 22310,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "A total of 480 participants were included in this post hoc analysis, with 327 participants receiving HBsAg/CpG 1018 and 153 participants receiving HBsAg/alum (Fig. 1).",
            "startOffset": 22143,
            "title": "Participants"
        },
        {
            "endOffset": 29269,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 29268,
                    "startOffset": 29265
                }
            },
            "secId": "s0075",
            "sentence": "In 2011, the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommended that unvaccinated adults with DM aged 19\u201359 years receive the HBV vaccine and unvaccinated adults with DM aged 60 years and older may be vaccinated for hepatitis B at the discretion of the treating physician [7].",
            "startOffset": 28944,
            "title": "Discussion"
        },
        {
            "endOffset": 15713,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 15712,
                    "startOffset": 15705
                },
                "b0055": {
                    "endOffset": 15712,
                    "startOffset": 15705
                },
                "b0060": {
                    "endOffset": 15712,
                    "startOffset": 15705
                }
            },
            "secId": "s0005",
            "sentence": "HBV infection outbreaks occur among elderly patients with DM in institutional healthcare settings, such as assisted-living facilities and nursing homes, where breaches of infection control practices associated with sharing of blood glucose monitors and other diabetes related\u2013care equipment have been documented [10\u201312].",
            "startOffset": 15393,
            "title": "Introduction"
        },
        {
            "endOffset": 27468,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 27467,
                    "startOffset": 27460
                },
                "b0055": {
                    "endOffset": 27467,
                    "startOffset": 27460
                },
                "b0060": {
                    "endOffset": 27467,
                    "startOffset": 27460
                }
            },
            "secId": "s0075",
            "sentence": "Many adults, including older persons with diabetes, do not achieve seroprotection with 3-dose vaccines [10\u201312].",
            "startOffset": 27357,
            "title": "Discussion"
        },
        {
            "endOffset": 29996,
            "parents": [],
            "secId": "s0075",
            "sentence": "The exact reasons for this low vaccination coverage and completion rates are not clear, though the immunogenicity and safety data presented here would support new prevention options for policymakers.",
            "startOffset": 29797,
            "title": "Discussion"
        },
        {
            "endOffset": 20347,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0035",
            "sentence": "The SPR induced by HBsAg/CpG 1018 at week 28 was compared with the SPR induced by HBsAg/alum at week 28 among participants who were aged 60\u201370 years and by subgroups, including sex, body mass index (BMI), and smoking status.",
            "startOffset": 20123,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22562,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the mITT analysis, 319 participants were in the HBsAg/CpG 1018 group and 150 participants were in the HBsAg/alum group, whereas in the PP analysis, 274 participants were in the HBsAg/CpG 1018 group and 130 participants were in the HBsAg/alum group.",
            "startOffset": 22311,
            "title": "Participants"
        },
        {
            "endOffset": 25063,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The most commonly reported MAEs in the HBsAg/alum group were type 2 DM, back pain, bronchitis, sinusitis, and osteoarthritis.",
            "startOffset": 24938,
            "title": "Safety"
        },
        {
            "endOffset": 30606,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 30605,
                    "startOffset": 30601
                }
            },
            "secId": "s0075",
            "sentence": "Future studies would be warranted to determine the immunogenicity and safety of HBsAg/CpG in participants of American Indian/Alaskan Native, non-Hispanic black, and Hispanic backgrounds with the highest rates of diagnosed diabetes according to the National Diabetes Statistics Report, 2017 [34].",
            "startOffset": 30311,
            "title": "Discussion"
        },
        {
            "endOffset": 26188,
            "parents": [],
            "secId": "s0075",
            "sentence": "Findings from this analysis demonstrated that HBsAg/CpG 1018 induced markedly higher levels of seroprotection against HBV than did HBsAg/alum in participants with type 2 DM who were aged 60\u201370 years.",
            "startOffset": 25989,
            "title": "Discussion"
        },
        {
            "endOffset": 16032,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 16031,
                    "startOffset": 16028
                }
            },
            "secId": "s0005",
            "sentence": "The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommends HBV vaccination of unvaccinated adults with DM aged 19\u201359 years, and unvaccinated adults with DM who are aged 60 years or older may be administered the HBV vaccination at the discretion of the treating physician [7].",
            "startOffset": 15713,
            "title": "Introduction"
        },
        {
            "endOffset": 24822,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The most commonly reported MAEs in the HBsAg/CpG 1018 group were upper respiratory tract infection, back pain, bronchitis, urinary tract infection, and hypertension (Table 2).",
            "startOffset": 24647,
            "title": "Safety"
        },
        {
            "endOffset": 22642,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Demographic and baseline characteristics were similar between groups (Table 1).",
            "startOffset": 22563,
            "title": "Participants"
        },
        {
            "endOffset": 19056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Participants provided written informed consent prior to enrollment.",
            "startOffset": 18989,
            "title": "Participants"
        },
        {
            "endOffset": 19923,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "HBsAg/alum (20 \u00b5g HBsAg adsorbed on 500 \u00b5g aluminum hydroxide per 1.0-mL dose) was injected intramuscularly into the deltoid muscle at 0, 4, and 24 weeks.",
            "startOffset": 19769,
            "title": "Study vaccine administration"
        },
        {
            "endOffset": 19768,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "HBsAg/CpG 1018 (20 \u00b5g of subtype adw recombinant HBsAg and 3 mg of a proprietary phosphorothioate oligodeoxynucleotide adjuvant, known as CpG-1018, per 0.5-mL dose) was administered intramuscularly into the deltoid muscle at 0 and 4 weeks, followed by placebo at 24 weeks to maintain blinding.",
            "startOffset": 19475,
            "title": "Study vaccine administration"
        },
        {
            "endOffset": 30762,
            "parents": [],
            "secId": "s0075",
            "sentence": "Even though the sample size in this post hoc analysis was relatively small, this study was the largest to date in patients with type 2 DM aged 60\u201370 years.",
            "startOffset": 30607,
            "title": "Discussion"
        },
        {
            "endOffset": 23980,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the mITT analysis, the GMC at week 28 was 126.7 mIU/mL in the HBsAg/CpG 1018 group and 44.1 mIU/mL in the HBsAg/alum group, with a GMC ratio of 2.9 (95% CI, 1.8\u20134.6).",
            "startOffset": 23811,
            "title": "Immunogenicity by geometric mean concentration"
        },
        {
            "endOffset": 17887,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 17886,
                    "startOffset": 17879
                },
                "b0120": {
                    "endOffset": 17886,
                    "startOffset": 17879
                }
            },
            "secId": "s0015",
            "sentence": "This study was a post hoc analysis of data collected during a large phase 3, observer-blinded, randomized, active-controlled, multicenter trial of the safety and immunogenicity of HBsAg/CpG 1018 in adults with and without type 2 DM (NCT02117934) [21,24].",
            "startOffset": 17633,
            "title": "Study design"
        },
        {
            "endOffset": 17448,
            "parents": [],
            "secId": "s0005",
            "sentence": "We assessed the safety and efficacy of HBsAg/CpG 1018 among adults with type 2 DM who are aged 60\u201370 years compared with HBsAg/alum.",
            "startOffset": 17316,
            "title": "Introduction"
        },
        {
            "endOffset": 19474,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Randomization was stratified by site, age group (18\u201339, 40\u201370 years), and type 2 DM status.",
            "startOffset": 19383,
            "title": "Study vaccine administration"
        },
        {
            "endOffset": 22752,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The mean age of participants was 64.5 years (range: 60\u201370 years), and most were obese, with a BMI \u2265 30 kg/m2.",
            "startOffset": 22643,
            "title": "Participants"
        },
        {
            "endOffset": 27050,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 27049,
                    "startOffset": 27042
                },
                "b0135": {
                    "endOffset": 27049,
                    "startOffset": 27042
                }
            },
            "secId": "s0075",
            "sentence": "Both the World Health Organization and the National Academies of Sciences, Engineering, and Medicine have declared hepatitis a major public health problem and have called for its elimination by 2030 [26,27].",
            "startOffset": 26843,
            "title": "Discussion"
        },
        {
            "endOffset": 29687,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 29686,
                    "startOffset": 29682
                }
            },
            "secId": "s0075",
            "sentence": "A claims-based study of US hepatitis vaccination series completion rates from 2007 to 2015 demonstrated that the 3-dose hepatitis B series completion rate ranged from 39.6% to 48.9% in the commercial/Medicare enrollee cohort [35].",
            "startOffset": 29457,
            "title": "Discussion"
        },
        {
            "endOffset": 21701,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Participants in the cohort aged 60\u201370 years with type 2 DM who did not deviate from the study protocol, received all injections, and had blood drawn for anti-HBs levels at week 28 were included in the per-protocol (PP) analysis.",
            "startOffset": 21473,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28716,
            "parents": [],
            "secId": "s0075",
            "sentence": "Improved HBV vaccines that demonstrated higher and earlier seroprotection in older adults with DM may help address this growing public health problem.",
            "startOffset": 28566,
            "title": "Discussion"
        },
        {
            "endOffset": 29796,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 29795,
                    "startOffset": 29791
                }
            },
            "secId": "s0075",
            "sentence": "Most individuals with DM aged 60 years and older are not vaccinated and remain unprotected against HBV [16].",
            "startOffset": 29688,
            "title": "Discussion"
        },
        {
            "endOffset": 21248,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0040",
            "sentence": "The proportion of participants with new-onset (reported from the time of first injection [week 0] to week 56), treatment-emergent medically attended AEs (MAEs), including cardiovascular events, immune-mediated AEs of special interest, and deaths were recorded.",
            "startOffset": 20988,
            "title": "Safety"
        },
        {
            "endOffset": 19382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants in the overall phase 3 study were randomized in a 2:1 ratio to receive either 2-dose HBsAg/CpG 1018 (Lot #1017098, manufactured by Rentschler Biotechnologie GMbH, Laupheim, Germany) or 3-dose HBsAg/alum (Lot #592D3, manufactured by GlaxoSmithKline Biologics, Philadelphia, PA, USA).",
            "startOffset": 19087,
            "title": "Study vaccine administration"
        },
        {
            "endOffset": 31214,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 31213,
                    "startOffset": 31207
                },
                "b0190": {
                    "endOffset": 31213,
                    "startOffset": 31207
                }
            },
            "secId": "s0075",
            "sentence": "At present, these initiatives do not include vaccination of people with DM, although HBV outbreaks due to capillary blood sampling have been reported not only in the United States, but in countries in the European Union as well [7,38].",
            "startOffset": 30979,
            "title": "Discussion"
        },
        {
            "endOffset": 25289,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No MAEs related to the study treatment were cardiovascular events.",
            "startOffset": 25223,
            "title": "Safety"
        },
        {
            "endOffset": 25366,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No serious AEs related to the study treatment were reported in either group.",
            "startOffset": 25290,
            "title": "Safety"
        },
        {
            "endOffset": 25621,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "This participant was diagnosed with polymyalgia rheumatica and, to date, is receiving ongoing treatment and monitoring.",
            "startOffset": 25502,
            "title": "Safety"
        },
        {
            "endOffset": 27177,
            "parents": [],
            "secId": "s0075",
            "sentence": "Vaccination is a proven tool in populations in whom the current vaccines work well, such as children and healthy young adults.",
            "startOffset": 27051,
            "title": "Discussion"
        },
        {
            "endOffset": 24937,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In the HBsAg/alum group, 85 (55.6%) participants experienced MAEs, 34 (22.2%) of whom reported a grade 3 or 4 MAE.",
            "startOffset": 24823,
            "title": "Safety"
        },
        {
            "endOffset": 32467,
            "parents": [],
            "secId": "s0080",
            "sentence": "Provided by Dynavax Technologies Corporation.",
            "startOffset": 32422,
            "title": "Financial support"
        },
        {
            "endOffset": 32241,
            "parents": [],
            "secId": "s0075",
            "sentence": "Our findings suggest careful consideration of the potential benefits of administering the 2-dose HBsAg/CpG 1018 vaccine to protect against HBV in patients with type 2 DM who are aged 60\u201370 years and to other traditionally hyporesponsive and at-risk individuals including men, people with obesity, and smokers.",
            "startOffset": 31932,
            "title": "Discussion"
        },
        {
            "endOffset": 16365,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 16364,
                    "startOffset": 16360
                }
            },
            "secId": "s0005",
            "sentence": "Nearly 90% of individuals with DM who are aged 60 years or older remain unvaccinated for HBV [16].",
            "startOffset": 16267,
            "title": "Introduction"
        },
        {
            "endOffset": 16266,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 16109,
                    "startOffset": 16102
                },
                "b0070": {
                    "endOffset": 16109,
                    "startOffset": 16102
                },
                "b0075": {
                    "endOffset": 16265,
                    "startOffset": 16261
                }
            },
            "secId": "s0005",
            "sentence": "However, because of ongoing challenges of vaccinating at-risk adults [13,14], low rates of adherence to Advisory Committee on Immunization Practices guidelines for HBV immunization and vaccine coverage in people with DM persist [15].",
            "startOffset": 16033,
            "title": "Introduction"
        },
        {
            "endOffset": 18592,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Participants included in this analysis were adults with a clinical diagnosis of type 2 DM who were taking insulin and/or a hypoglycemic agent and who were aged 60 to 70 years (Fig. 1).",
            "startOffset": 18408,
            "title": "Participants"
        },
        {
            "endOffset": 25978,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "There were 3 deaths (due to hepatic cirrhosis, acute respiratory distress syndrome, and cardiac arrest) in the HBsAg/CpG 1018 group not considered related to treatment and 1 death (due to cardiorespiratory arrest) in the HBsAg/alum group not considered related to treatment.",
            "startOffset": 25704,
            "title": "Safety"
        },
        {
            "endOffset": 22120,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "For the HBsAg/CpG 1018 to HBsAg/alum GMC ratio, 95% CIs were calculated using the Miettinen and Nurminen method without stratification.",
            "startOffset": 21985,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32405,
            "parents": [],
            "secId": "s0075",
            "sentence": "Future studies are needed to determine the potential benefits of administering the 2-dose HBsAg/CpG 1018 vaccine to patients with type 2 DM who are aged >70 years.",
            "startOffset": 32242,
            "title": "Discussion"
        },
        {
            "endOffset": 17083,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 17082,
                    "startOffset": 17075
                },
                "b0090": {
                    "endOffset": 17082,
                    "startOffset": 17075
                },
                "b0095": {
                    "endOffset": 17082,
                    "startOffset": 17075
                },
                "b0100": {
                    "endOffset": 17082,
                    "startOffset": 17075
                },
                "b0105": {
                    "endOffset": 17082,
                    "startOffset": 17075
                }
            },
            "secId": "s0005",
            "sentence": "It provides a markedly higher level of seroprotection, particularly in historically hyporesponsive populations\u2014including older adults, men, people with obesity, adults with diabetes, and smokers\u2014than the most commonly used 3-dose vaccine (HBsAg/alum, Engerix-B\u00ae, GlaxoSmithKline Biologicals, Rixensart, Belgium), which is administered over 24 weeks [17\u201321].",
            "startOffset": 16726,
            "title": "Introduction"
        },
        {
            "endOffset": 23034,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At week 28, in the PP analysis, the SPR in the HBsAg/CpG 1018 group (85.5% [235/274]) was significantly higher than the SPR in the HBsAg/alum group (58.5% [76/130]), with a treatment effect difference of 27.3% (95% CI, 18.0\u201336.8%) (Fig. 2A).",
            "startOffset": 22793,
            "title": "Immunogenicity by seroprotection rates"
        },
        {
            "endOffset": 16680,
            "parents": [],
            "secId": "s0005",
            "sentence": "HBsAg/CpG 1018 (HEPLISAV-B\u00ae, Dynavax Technologies Corporation, Berkeley, California, USA) is the only 2-dose HBV vaccine approved for adults by the US Food and Drug Administration.",
            "startOffset": 16500,
            "title": "Introduction"
        },
        {
            "endOffset": 24418,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The shallow slope of the HBsAg/alum curve indicates a larger variance in the antibody response to HBsAg/alum compared with HBsAg/CpG-1018.",
            "startOffset": 24280,
            "title": "Immunogenicity by geometric mean concentration"
        },
        {
            "endOffset": 21871,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "For SPRs and their 95% confidence intervals (CIs), the 2-sided Clopper-Pearson method and the Miettinen and Nurminen method without stratification were used respectively.",
            "startOffset": 21701,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 30978,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 30977,
                    "startOffset": 30973
                }
            },
            "secId": "s0075",
            "sentence": "To further foster the global endeavor of eliminating viral hepatitis by 2030, many European health agencies have begun implementing hepatitis prevention measures to reduce infection incidence in key risk groups [37].",
            "startOffset": 30762,
            "title": "Discussion"
        },
        {
            "endOffset": 31932,
            "parents": [],
            "secId": "s0075",
            "sentence": "With HBV outbreaks in people with DM similar to those in the United States, European healthcare providers and policymakers may need to consider strategies to protect people with diabetes against hepatitis B and, if desired, create a framework to provide HBV vaccination to these patients.",
            "startOffset": 31644,
            "title": "Discussion"
        },
        {
            "endOffset": 14569,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 14568,
                    "startOffset": 14565
                }
            },
            "secId": "s0005",
            "sentence": "The World Health Organization estimates that 257 million people are seropositive for hepatitis B surface antigen (HBsAg), a marker of active HBV infection, and roughly 887,000 people died from hepatitis B complications in 2015 alone [1].",
            "startOffset": 14332,
            "title": "Introduction"
        },
        {
            "endOffset": 16725,
            "parents": [],
            "secId": "s0005",
            "sentence": "HBsAg/CpG 1018 is administered over 4 weeks.",
            "startOffset": 16681,
            "title": "Introduction"
        },
        {
            "endOffset": 18988,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "We excluded participants if they had a history of HBV or human immunodeficiency virus (HIV) infection or an autoimmune disorder; were seropositive for HBsAg, antibody against hepatitis B surface antigen (anti-HBs), antibody against hepatitis B core antigen (anti-HBc), or antibody against HIV (anti-HIV); or previously received any hepatitis B vaccine, DNA plasmid, or oligonucleotide injection.",
            "startOffset": 18593,
            "title": "Participants"
        },
        {
            "endOffset": 15392,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 15391,
                    "startOffset": 15386
                },
                "b0045": {
                    "endOffset": 15391,
                    "startOffset": 15386
                }
            },
            "secId": "s0005",
            "sentence": "Patients with DM have more severe HBV-related morbidity, including increased risk of liver cirrhosis and hepatocellular carcinoma, and accelerated disease progression and death compared to those without DM [8,9].",
            "startOffset": 15180,
            "title": "Introduction"
        },
        {
            "endOffset": 28315,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 28204,
                    "startOffset": 28197
                },
                "b0160": {
                    "endOffset": 28204,
                    "startOffset": 28197
                },
                "b0165": {
                    "endOffset": 28314,
                    "startOffset": 28310
                }
            },
            "secId": "s0075",
            "sentence": "The prevalence of DM is steadily increasing [31,32] and the proportion of the world\u2019s population aged 65 years and older is growing at an unprecedented rate [33].",
            "startOffset": 28153,
            "title": "Discussion"
        },
        {
            "endOffset": 28152,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 28151,
                    "startOffset": 28147
                }
            },
            "secId": "s0075",
            "sentence": "For instance, in a randomized, observer-blinded study, just 32.4% of healthy adults who received HBsAg/alum were seroprotected at 24 weeks after the second dose, whereas 81.1% were seroprotected 4 weeks after the third dose [30].",
            "startOffset": 27923,
            "title": "Discussion"
        },
        {
            "endOffset": 30214,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 30213,
                    "startOffset": 30209
                }
            },
            "secId": "s0075",
            "sentence": "This exploratory post hoc subgroup analysis has inherent constraints, including overemphasizing the differences between the 2 treatment groups and limited generalizability due to the stringent enrollment criteria [36].",
            "startOffset": 29996,
            "title": "Discussion"
        },
        {
            "endOffset": 27356,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 27355,
                    "startOffset": 27350
                },
                "b0015": {
                    "endOffset": 27355,
                    "startOffset": 27350
                }
            },
            "secId": "s0075",
            "sentence": "Despite effective childhood vaccination programs, the prevalence of hepatitis B in the United States is increasing, with the majority of new infections occurring in adults [2,3].",
            "startOffset": 27178,
            "title": "Discussion"
        },
        {
            "endOffset": 20635,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0035",
            "sentence": "Therefore, the SPRs as well as the anti-HBs serum geometric mean concentrations (GMCs) induced by HBsAg/CpG 1018 at week 24 and by HBsAg/alum at week 28 were also compared.",
            "startOffset": 20463,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 17315,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 17314,
                    "startOffset": 17310
                }
            },
            "secId": "s0005",
            "sentence": "For example, in a recent study of adults with type 2 DM, 90% of participants were seroprotected after completing 2-dose HBsAg/CpG 1018 compared with 65.1% of participants who completed 3-dose HBsAg/alum (95% CI: 19.3%, 30.7%) [21].",
            "startOffset": 17084,
            "title": "Introduction"
        },
        {
            "endOffset": 18027,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The overall study included 5592 adults randomized to receive 2-dose HBsAg/CpG 1018 and 2782 adults randomized to receive 3-dose HBsAg/alum.",
            "startOffset": 17888,
            "title": "Study design"
        },
        {
            "endOffset": 23639,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the PP analysis, the GMC at week 28 was 131.9 mIU/mL in the HBsAg/CpG 1018 group and 51.6 mIU/mL in the HBsAg/alum group, with a GMC ratio of 2.6 (95% CI, 1.5\u20134.3; Fig. 4).",
            "startOffset": 23464,
            "title": "Immunogenicity by geometric mean concentration"
        },
        {
            "endOffset": 15002,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14955,
                    "startOffset": 14948
                },
                "b0020": {
                    "endOffset": 14955,
                    "startOffset": 14948
                },
                "b0025": {
                    "endOffset": 14955,
                    "startOffset": 14948
                },
                "b0030": {
                    "endOffset": 15001,
                    "startOffset": 14996
                },
                "b0035": {
                    "endOffset": 15001,
                    "startOffset": 14996
                }
            },
            "secId": "s0005",
            "sentence": "Adults with diabetes mellitus (DM) are at a greater risk of contracting HBV than the general population [2,4,5], including those aged 60 years or older [6,7].",
            "startOffset": 14844,
            "title": "Introduction"
        },
        {
            "endOffset": 23810,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In each subgroup (sex, BMI stratum, and smoking status), the GMC at week 28 in the HBsAg/CpG 1018 group was markedly higher than the GMC in the HBsAg/alum group (Fig. 4).",
            "startOffset": 23640,
            "title": "Immunogenicity by geometric mean concentration"
        },
        {
            "endOffset": 26730,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 26729,
                    "startOffset": 26719
                },
                "b0100": {
                    "endOffset": 26729,
                    "startOffset": 26719
                },
                "b0105": {
                    "endOffset": 26729,
                    "startOffset": 26719
                },
                "b0115": {
                    "endOffset": 26729,
                    "startOffset": 26719
                }
            },
            "secId": "s0075",
            "sentence": "The immunogenicity and safety findings of this post hoc analysis are consistent with results from the overall phase 3 study population and several previous phase 3 studies of HBsAg/CpG [19\u201321,23].",
            "startOffset": 26534,
            "title": "Discussion"
        },
        {
            "endOffset": 23415,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In each subgroup (sex, BMI stratum, and smoking status), the SPR at week 28 was markedly higher in participants who received HBsAg/CpG 1018 than in those who received HBsAg/alum (Fig. 3).",
            "startOffset": 23228,
            "title": "Immunogenicity by seroprotection rates"
        },
        {
            "endOffset": 20820,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 20676,
                    "startOffset": 20672
                }
            },
            "secId": "s0035",
            "sentence": "A reverse cumulative frequency plot [25] was used to summarize, assess, and compare the distribution of anti-HBs concentrations in response to HBsAg/CpG 1018 and HBsAg/alum at week 28.",
            "startOffset": 20636,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32620,
            "parents": [],
            "secId": "s0085",
            "sentence": "The design, study conduct, analysis, and financial support for this study were provided by Dynavax Technologies Corporation, Berkeley, California.",
            "startOffset": 32474,
            "title": "Funding"
        },
        {
            "endOffset": 25222,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Two participants (0.6%) in the HBsAg/CpG 1018 group and 5 participants (3.3%) in the HBsAg/alum group reported an MAE that was related to the study treatment.",
            "startOffset": 25064,
            "title": "Safety"
        },
        {
            "endOffset": 26842,
            "parents": [],
            "secId": "s0075",
            "sentence": "Although hepatitis B is a vaccine-preventable disease, HBV infection remains a major global public health issue.",
            "startOffset": 26730,
            "title": "Discussion"
        },
        {
            "endOffset": 24279,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The slope of the HBsAg/CpG 1018 curve was steeper than the HBsAg/alum curve, indicating that the antibody response to HBsAg/CpG 1018 was less variable than the response to HBsAg/alum.",
            "startOffset": 24096,
            "title": "Immunogenicity by geometric mean concentration"
        },
        {
            "endOffset": 17610,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 17609,
                    "startOffset": 17602
                },
                "b0115": {
                    "endOffset": 17609,
                    "startOffset": 17602
                }
            },
            "secId": "s0005",
            "sentence": "This subpopulation of adults is characteristically hyporesponsive to 3-dose alum-adjuvanted HBsAg/alum, with reduced rates of seroprotection against HBV [22,23].",
            "startOffset": 17449,
            "title": "Introduction"
        },
        {
            "endOffset": 16500,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 16499,
                    "startOffset": 16492
                },
                "b0055": {
                    "endOffset": 16499,
                    "startOffset": 16492
                },
                "b0060": {
                    "endOffset": 16499,
                    "startOffset": 16492
                }
            },
            "secId": "s0005",
            "sentence": "Compounding these challenges, seroprotection rates (SPRs) after hepatitis B vaccination steadily decrease with increasing age [10\u201312].",
            "startOffset": 16366,
            "title": "Introduction"
        },
        {
            "endOffset": 20122,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes"
                }
            ],
            "secId": "s0035",
            "sentence": "Seroprotection was defined as anti-HBs serum concentration \u226510 mIU/mL.",
            "startOffset": 20052,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31643,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 31642,
                    "startOffset": 31635
                },
                "b0200": {
                    "endOffset": 31642,
                    "startOffset": 31635
                }
            },
            "secId": "s0075",
            "sentence": "In several countries in the European Union, there are currently no recommendations for HBV vaccination of people with DM [39,40].",
            "startOffset": 31514,
            "title": "Discussion"
        },
        {
            "endOffset": 29456,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 29415,
                    "startOffset": 29411
                }
            },
            "secId": "s0075",
            "sentence": "Yet, findings from multiple studies have shown that adherence to this national guideline remains low due in part to low vaccination coverage [15] and low vaccine series completion rates.",
            "startOffset": 29270,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19310448",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "rhyer@dynavax.com",
                "first": "Randall N.",
                "initial": "R.N.",
                "last": "Hyer"
            },
            {
                "email": "rjanssen@dynavax.com",
                "first": "Robert S.",
                "initial": "R.S.",
                "last": "Janssen"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.08.005",
        "firstpage": "5854",
        "issn": "0264410X",
        "keywords": [
            "Advisory Committee on Immunization Practices",
            "Diabetes mellitus",
            "Health services for the aged",
            "Hepatitis B",
            "Hepatitis B vaccines",
            "Vaccination"
        ],
        "lastpage": "5861",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60\u201370\u202fyears"
    }
}